{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=42",
    "query": {
      "condition": "Pharmacokinetics and Pharmacodynamics",
      "page": 42
    },
    "page_size": 10
  },
  "pagination": {
    "page": 42,
    "page_size": 10,
    "total_count": 2339,
    "total_pages": 234,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=43&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pharmacokinetics+and+Pharmacodynamics&page=41&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T13:38:24.093Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04840914",
      "title": "A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Heart Failure With Reduced Ejection Fraction"
      ],
      "interventions": [
        {
          "name": "LY3461767",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 44,
      "start_date": "2021-06-01",
      "completion_date": "2024-05-09",
      "has_results": false,
      "last_update_posted_date": "2024-05-30",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 3,
      "location_summary": "Detroit, Michigan • St Louis, Missouri • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04840914"
    },
    {
      "nct_id": "NCT04444752",
      "title": "A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Moderate-to-severe Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "CBP-201",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Connect Biopharm LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 226,
      "start_date": "2020-07-17",
      "completion_date": "2021-09-22",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 38,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 32 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Canoga Park",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04444752"
    },
    {
      "nct_id": "NCT01439152",
      "title": "Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Oncology"
      ],
      "interventions": [
        {
          "name": "BAY94-9343",
          "type": "DRUG"
        },
        {
          "name": "BAY94-9343 (Expansion)",
          "type": "DRUG"
        },
        {
          "name": "BAY94-9343 (1.8 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "BAY94-9343 (2.2 mg/kg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2011-09-07",
      "completion_date": "2019-07-30",
      "has_results": false,
      "last_update_posted_date": "2021-07-09",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 8,
      "location_summary": "New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01439152"
    },
    {
      "nct_id": "NCT03541369",
      "title": "Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "AMG 427",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-09-14",
      "completion_date": "2023-02-21",
      "has_results": true,
      "last_update_posted_date": "2024-10-10",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Evanston, Illinois • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03541369"
    },
    {
      "nct_id": "NCT07191483",
      "title": "A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cognitive Impairment Associated With Schizophrenia (CIAS)"
      ],
      "interventions": [
        {
          "name": "KYN-5356 low dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "KYN-5356 Medium Dose",
          "type": "DRUG"
        },
        {
          "name": "KYN-5356 High Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Kynexis B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 150,
      "start_date": "2025-08-27",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 15,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 12 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07191483"
    },
    {
      "nct_id": "NCT06305351",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of K-757 and K-833 in Overweight/Obese Patients With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Obesity",
        "Type 2 Diabetes Mellitus (T2DM)"
      ],
      "interventions": [
        {
          "name": "K-757 and K-833 QD",
          "type": "DRUG"
        },
        {
          "name": "K-757 and K-833 BID",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo to K-757 and K-833 QD",
          "type": "DRUG"
        },
        {
          "name": "Matching placebo to K-757 and K-833 BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kallyope Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 25,
      "start_date": "2023-12-07",
      "completion_date": "2024-06-21",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305351"
    },
    {
      "nct_id": "NCT06450639",
      "title": "A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Satralizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "MALE",
        "summary": "8 Years to 17 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2025-04-04",
      "completion_date": "2026-11-18",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Sacramento, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Flower Mound",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06450639"
    },
    {
      "nct_id": "NCT02576639",
      "title": "Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "CNP520",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "60 Years to 80 Years"
      },
      "enrollment_count": 124,
      "start_date": "2015-08-10",
      "completion_date": "2016-03-11",
      "has_results": true,
      "last_update_posted_date": "2017-08-11",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 4,
      "location_summary": "Glendale, California • Long Beach, California • Miami, Florida + 1 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02576639"
    },
    {
      "nct_id": "NCT06299839",
      "title": "PAS-004 in Patients With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RAS Mutation",
        "NF1 Mutation",
        "RAF Mutation",
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "PAS-004 Capsules",
          "type": "DRUG"
        },
        {
          "name": "PAS-004 Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pasithea Therapeutics Corp.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2024-02-29",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2025-12-03",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 4,
      "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Irving",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06299839"
    },
    {
      "nct_id": "NCT00610194",
      "title": "Phase 1 Dose-escalation PK/PD Trial in Advanced Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "RDEA119",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2007-11-28",
      "completion_date": "2012-08-01",
      "has_results": false,
      "last_update_posted_date": "2023-10-18",
      "last_synced_at": "2026-10-17T13:38:24.093Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Buffalo, New York",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00610194"
    }
  ]
}